Top Tweets for #askDRGExperts

over 8 years ago

Breaking news: FDA approves Novartis' #Tafinlar + #Mekinist for anaplastic thyroid cancer. This news comes hot on the heels of the melanoma adjuvant approval for this combination #AskDRGExperts @DRGinsights

Andrew_Merron's tweet photo. Breaking news: FDA approves Novartis' #Tafinlar + #Mekinist for anaplastic thyroid cancer. This news comes hot on the heels of the melanoma adjuvant approval for this combination #AskDRGExperts @DRGinsights https://t.co/caI63uN84U

0

2

3

0

over 8 years ago

BREAKING: @Novartis #Kymriah FDA approved for 2nd indication R/R large B-cell lymphoma. Now in direct competition with #Yescarta matching $373k price tag. See DRG's upcoming CAR T-cell therapy report for more. @DRGInsights #AskDRGExperts https://t.co/zQIzkOpy85

0

3

0

over 8 years ago

#FDA grants Sanofi & Regeneron priority review for a new PD-1 inhibitor #cemiplimab based on a pivotal Phase 2 single arm trial. Which other checkpoint inhibitors are in Phase 2 trials single arm trials? We have the data! @DRGinsights #askDRGExperts

Andrew_Merron's tweet photo. #FDA grants Sanofi & Regeneron priority review for a new PD-1 inhibitor #cemiplimab based on a pivotal Phase 2 single arm trial. Which other checkpoint inhibitors are in Phase 2 trials single arm trials? We have the data! @DRGinsights #askDRGExperts https://t.co/sizoQ6byUl

0

4

2

0

over 8 years ago

What does today’s Phase 3 failure of #epacadostat in combo with #Keytruda mean for the 30+ checkpoint inhibitors in combo with IDO inhibitor trials? #AskDRGExperts @DRGInsights

Andrew_Merron's tweet photo. What does today’s Phase 3 failure of #epacadostat in combo with #Keytruda mean for the 30+ checkpoint inhibitors in combo with IDO inhibitor trials? #AskDRGExperts @DRGInsights https://t.co/g2ArfP5VQq

0

5

6

0

over 8 years ago

Phase 3 #epacadostat @Incyte + #Keytruda #melanoma trial fails to meet PFS. Trial stopped! What is the future for IDO-1 in oncology now? @DRGInsights #AskDRGExperts https://t.co/fx5D4GNr06

0

1

5

0

over 8 years ago

The #biosimilars pipeline continues to be both diverse and deep #AskDRGExperts

1

3

4

0

Nature Reviews Drug Discovery @NatRevDrugDisc

over 8 years ago

Check out @RWebsterDRG @NatRevDrugDisc for insights into the CAR T-cell therapy market @DRGInsights #AskDRGexperts https://t.co/yJ3jyXOLbL

over 8 years ago

The market for chimeric antigen receptor T cell therapies https://t.co/GyfTaMyYll

2

43

31

0

4

0

almost 9 years ago

Here's our latest global #biosimilars pipeline update #AskDRGExperts

0

8

0

almost 9 years ago

Where are the #biosmilar drug development hotspots? We've just updated this graphic based on our latest pipeline updates #askDRGexperts

DRGBiosimilars's tweet photo. Where are the #biosmilar drug development hotspots? We've just updated this graphic based on our latest pipeline updates #askDRGexperts https://t.co/AKp0eGrvfn

0

1

2

0

about 9 years ago

Disappointing day for Bavarian Nordic & #prostatecancer patients: Prostvac Phase III study (PROSPECT) to be discontinued. #askDRGexperts

1

0

about 9 years ago

#ESMO17 #Cyramza (RANGE) vs. #Keytruda (KEYNOTE-045). #Keytruda looks like the preferred 2L therapy for #urothelialcarcinoma #AskDRGExperts

RachelMWebster1's tweet photo. #ESMO17 #Cyramza (RANGE) vs. #Keytruda (KEYNOTE-045). #Keytruda looks like the preferred 2L therapy for #urothelialcarcinoma #AskDRGExperts https://t.co/wXHnnojIE1

1

7

5

0

about 9 years ago

#ESMO17 CheckMate-214 #Opdivo + #Yervoy new SOC or "option" in 1L mRCC? #AskDRGExperts @DRGInsights

0

3

0

about 9 years ago

Very interesting blog on JAK inhibitors in IBD. Are they a threat to biologics? #AskDRGExperts @DRGinsights https://t.co/k3W4MMxZIC

0

1

0

about 9 years ago

First CAR T-cell therapy MAA submitted in Europe @KitePharma axi-cel for R/R #DLBCL @DRGInsights #AskDRGExperts https://t.co/EomdzapLbM

0

6

4

0

about 9 years ago

Ahead of FDA advisory panel meeting for @Novartis #CTL019 CAR T-cell concerns raised about long term safety @DRGinsights #AskDRGExperts

0

1

0

about 9 years ago

Array BioPharma submits NDA for BRAF/MEK combo #binimetinib + #encorafenib for #melanoma #AskDRGExperts @DRGInsights https://t.co/oPZ5Nb8Nz0

0

3

2

0

about 9 years ago

via @JAMAOnc #nivolumab treatment beyond progression could benefit a proportion of #melanoma patients #AskDRGExperts @DRGinsights https://t.co/aI0JWJKTM3

JAMA Oncology @JAMAOnc

about 9 years ago

Pts treated beyond their 1st disease progression can experience #tumor response w cont #nivolumab Tx https://t.co/lUEhC74JmV

0

3

9

0

1

0

about 9 years ago

#Opdivo hits RFS vs. #Yervoy (10 mg/kg) in P3 trial for high risk resected stage III/IV #AskDRGExperts @DRGinsights https://t.co/imopOTTzFz

0

3

0